Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium

Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced it will host a conference call and webcast on Sat., Oct. 24 at 11:00… Continue reading Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium

Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium

Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced it will host a conference call and webcast on Sat., Oct. 24 at 11:00… Continue reading Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium

Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at… Continue reading Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer

Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that abstracts submitted for two of its drug candidates have been… Continue reading Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that abstracts submitted for two of its drug candidates have been… Continue reading Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that abstracts submitted for two of its drug candidates have been… Continue reading Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium

Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session on Oct. 5 as part of the Roth Capital Partners’ CEO… Continue reading Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session on Oct. 5 as part of the Roth Capital Partners’ CEO… Continue reading Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session on Oct. 5 as part of the Roth Capital Partners’ CEO… Continue reading Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session on Oct. 5 as part of the Roth Capital Partners’ CEO… Continue reading Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference